Belgian UCB gets ready for CEO change

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

UCB gets ready for CEO change

Belgian UCB Pharmaceuticals is preparing for a change in leadership. UCB's current executive vice president of biopharma brands and solutions, Jean-Christophe Tellier, will take over as CEO-elect and chairman of the executive committee on March 1 before becoming CEO on Jan. 1, 2015. Tellier replaces current chief Roch Doliveux, who has served as CEO since 2005. Tellier served in management positions at Ipsen and Novartis ($NVS) before joining UCB. Story

UCB
Jean-Christophe Tellier will become CEO-elect on March 1 before taking over as CEO on Jan. 1, 2015.


Biogen Idec
Stelios Papadopoulos will join Biogen Idec's board of directors as chairman.


Biotech

> Biogen Idec ($BIIB) tapped Stelios Papadopoulos to replace Bill Young as the chairman of the company's board of directors. Release

> Alcobra ($ADHD) has appointed Tomer Berkovitz as chief financial officer. Release

> Exco InTouch appointed Laurence Burke as its vice president of operations. Release

> AlloSource's vice president of R&D and marketing Peter Stevens joined the University of Denver advisory board for the professional sciences master's program in biomedical sciences. Release

> Dr. Bankole Johnson, the scientific founder and chairman of the board of ADial Pharmaceuticals, will head a new Brain Science Research Consortium Unit at the University of Maryland School of Medicine. Release

> Achaogen has appointed Derek Bertocci chief financial officer and John Smither as a member of the board of directors. Release

> Ignyta has appointed Dr. Sara Zaknoen chief medical officer. Release

> Navidea Biopharmaceuticals ($NAVB) has appointed Perry Karsen to the company's board of directors. Release

> Gliknik added Jeffrey Herpst as senior director of clinical development and Dr. Richard Levy to the company's board of directors. Release

Pharma

> Aurinia Pharmaceuticals' chief scientific officer Robert Foster stepped down to pursue other opportunities, according to the company. Release

> Imprimis Pharmaceuticals ($IMMY) named Randle House as the company's vice president of pharmacy operations. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.